Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
The Alathur facility specializes in the production of Cephalosporin antibiotics
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
Subscribe To Our Newsletter & Stay Updated